Data lead to answers.

Fundamental to public health research and policy, biostatistics is also one of the most interdisciplinary departments at Boston University School of Public Health. By designing studies, developing new methodologies, and extracting and analyzing information from data, we help inform decisions to promote better health.

Biostatistics faculty members are internationally recognized for methodological innovations in clinical trials and observational studies, statistical genetics analysis, and Bayesian methods. They have a long history of collaborating to address some of the world’s most pressing public health concerns, as well as training the next generation of students to tackle emerging public health and medical issues with cutting-edge methods and technological skills.

Areas in which we are active include genetic studies of risk factors for breast cancer; safety and efficacy assessments of a new Alzheimer’s disease drug; comparisons of patient outcomes with different behavioral interventions; and studies to identify genetic and non-genetic factors of healthy aging and extreme human longevity.

Affiliated Academic Programs:

MS in Biostatistics MS in Applied Biostatistics

PhD in Biostatistics Master of Public Health

Recent Department News

Latest Publications

  • Published On 6/3/2025Insulin Resistance Increases TNBC Aggressiveness and Brain Metastasis via Adipocyte-Derived Exosomes.Molecular cancer research : MCRread at PubMed
  • Published On 6/3/2025Association of MRI visible Perivascular Spaces with Early White Matter Injury.AJNR. American journal of neuroradiologyread at PubMed
  • Published On 6/1/2025Oral vs Extended-Release Injectable Naltrexone for Hospitalized Patients With Alcohol Use Disorder: A Randomized Clinical Trial.JAMA internal medicineread at PubMed
  • Published On 6/1/2025Contribution of Posttuberculosis Sequelae to Life-Years Lost from Tuberculosis Disease in the United States, 2015-2019.American journal of respiratory and critical care medicineread at PubMed
  • Published On 5/29/2025Antiproliferative endovascular drug technology is associated with fewer major reinterventions after femoropopliteal interventions for chronic limb-threatening ischemia.Journal of vascular surgeryread at PubMed